32 results
8-K
EX-99.1
GLTO
Galecto Inc
23 Oct 23
Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial
9:00am
of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Galecto's expectations. Factors that could cause
8-K
GLTO
Galecto Inc
26 Sep 23
Galecto Announces Plans to Explore Strategic Alternatives
4:05pm
the protection of the Private Securities Litigation Reform Act of 1995.
Any forward-looking statements in this current report are based on the Company’s current
8-K
EX-99.1
GLTO
Galecto Inc
26 Sep 23
Galecto Announces Plans to Explore Strategic Alternatives
4:05pm
words. For such statements, Galecto claims the protection of the Private Securities Litigation Reform Act of 1995.
Any forward-looking statements
8-K
EX-99.1
yevtue
15 Aug 23
Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis
8:00am
8-K
EX-99.1
fkncg0c 02yos2qs
31 Oct 22
Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD’s The Liver Meeting® 2022
9:00am
8-K
EX-99.1
qirpa
29 Sep 22
GB2064 Shows Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis, Validating LOXL2 as a Clinical Fibrosis Target
7:00am
8-K
EX-99.1
u7u4dv3n219dhiu
27 Jan 22
Results Support Favorable Safety and Tolerability Profile and Target Engagement of GB0139 and Potential for GB0139 in Severe Lung Disease
8:31am
8-K
EX-99.1
zwl52tj chwa15
5 Jan 22
Regulation FD Disclosure
4:02pm
S-3
oeabte
4 Nov 21
Shelf registration
4:59pm
S-3
EX-1.2
1mox5oc
4 Nov 21
Shelf registration
4:59pm
8-K
EX-10.1
az8ep
6 Jul 21
Departure of Directors or Certain Officers
9:00am
10-K
shql b8kb3
29 Mar 21
Annual report
6:03am
8-K
EX-99.1
5iqwczi9h7fltv8
15 Mar 21
Regulation FD Disclosure
7:52am
8-K
EX-99.1
hhn 1ukemiba
8 Jan 21
Galecto Appoints Anne Prener to its Board of Directors
8:15am